6-Methyl-5-Nitropyridin-2-Amine Industrial Purity and COA Requirements
- Critical QC Parameters: Assay purity must exceed 98.0% via HPLC/GC with defined impurity profiles for pharmaceutical intermediates.
- Synthesis Optimization: Controlled nitration of 2-amino-6-methylpyridine ensures consistent yield and minimizes oxidative byproducts.
- Bulk Supply Standards: Industrial-grade procurement requires validated COA documentation, proper storage protocols, and competitive bulk price structures.
In the pharmaceutical and agrochemical sectors, the reliability of heterocyclic intermediates dictates the success of downstream synthesis. 6-Methyl-5-Nitropyridin-2-Amine (CAS: 22280-62-2) serves as a critical building block for various kinase inhibitors and functionalized pyridine derivatives. For process chemists and procurement managers, understanding the specific industrial purity standards and Certificate of Analysis (COA) requirements is essential to mitigate supply chain risks. This technical overview details the physicochemical specifications, quality control methodologies, and manufacturing considerations necessary for securing high-quality bulk supplies.
Defining Industrial Purity Standards for CAS 22280-62-2
When evaluating suppliers for 2-amino-5-nitro-6-methylpyridine, the distinction between laboratory-grade and industrial-grade material is paramount. While research-scale quantities may tolerate minor variances, large-scale production demands strict adherence to defined specifications. The molecular formula C6H7N3O2 corresponds to a molecular weight of 153.14 g/mol. The physical appearance should be a consistent yellow powder or crystalline solid, with a melting point range typically observed between 185-189 °C.
Deviation in melting point often indicates the presence of isomeric impurities or residual solvents. A robust quality control framework ensures that the manufacturing process eliminates regioisomers such as 6-amino-3-nitro-2-methylpyridine, which can interfere with subsequent coupling reactions. Leading suppliers, such as NINGBO INNO PHARMCHEM CO.,LTD., maintain rigorous internal standards that often exceed generic pharmacopoeia requirements, ensuring that every batch meets the stringent needs of GMP-compliant synthesis.
Essential COA Parameters for Pharmaceutical Intermediates
A comprehensive COA is the primary document verifying the quality of the chemical shipment. For bulk procurement, the COA must detail more than just the main assay value. It should include data on loss on drying, residue on ignition, and specific impurity limits. Below is a representative table of critical quality attributes expected for industrial-grade material:
| Parameter | Specification | Test Method |
|---|---|---|
| Appearance | Yellow Powder/Crystals | Visual |
| Assay (Purity) | ≥ 98.0% | HPLC / GC |
| Melting Point | 185-189 °C | DSC / Capillary |
| Loss on Drying | ≤ 0.5% | Karl Fischer / LOD |
| Related Substances | Single Impurity ≤ 0.5% | HPLC Area Normalization |
| Heavy Metals | ≤ 10 ppm | ICP-MS |
Procurement teams should verify that the testing methods listed on the COA are validated. For instance, HPLC methods should specify the column type, mobile phase composition, and detection wavelength to ensure reproducibility across different batches. Inconsistencies in these parameters can lead to failed incoming quality control (IQC) checks at the manufacturing site.
HPLC Testing Methods and Impurity Profiles
The synthesis route for this compound typically involves the nitration of 2-amino-6-methylpyridine using a mixture of concentrated sulfuric acid and nitric acid. While effective, this exothermic reaction can generate oxidative byproducts and regioisomers if temperature control is lax during the addition phase. Consequently, the impurity profile is a key indicator of process control.
High-Performance Liquid Chromatography (HPLC) is the preferred method for quantifying these impurities. A standard method might utilize a C18 reversed-phase column with a gradient elution of water and acetonitrile, buffered to maintain peak shape for the basic pyridine nitrogen. The presence of 6-amino-2-methyl-3-nitropyridine or over-nitrated species must be monitored closely. When sourcing high-purity 6-methyl-5-nitro-pyridin-2-ylamine, buyers should request chromatograms alongside the COA to verify the separation efficiency and baseline resolution of critical pairs.
Furthermore, residual solvent analysis is critical. Given the use of strong acids and potential extraction solvents like ethyl acetate during workup, GC-headspace analysis should confirm that residual levels comply with ICH Q3C guidelines. This level of transparency distinguishes a reliable global manufacturer from smaller traders who may not perform full residual solvent profiling.
Bulk Procurement and Safety Considerations
Scaling from gram-scale laboratory synthesis to tonnage production introduces challenges in heat dissipation and mixing efficiency. Industrial reactors must be equipped to handle the exotherm of the nitration step safely. Suppliers capable of managing this manufacturing process at scale can offer a more stable bulk price and consistent lead times. Buyers should inquire about the supplier's capacity for campaign production and their ability to reserve inventory for long-term contracts.
Safety data is another non-negotiable component of the procurement package. The substance carries GHS hazard statements related to harm if swallowed, in contact with skin, or if inhaled (H302, H312, H332). Proper storage requires keeping the material in a dark place under an inert atmosphere at room temperature to prevent degradation. Packaging should be robust, typically utilizing fiber drums with polyethylene liners to prevent moisture uptake, which can affect the flowability and purity of the yellow powder.
Partnering with an established entity like NINGBO INNO PHARMCHEM CO.,LTD. ensures that these safety and quality protocols are integrated into the supply chain from synthesis to shipment. Their commitment to technical excellence provides buyers with the confidence needed for critical pharmaceutical applications.
Conclusion
Securing a reliable supply of 6-Methyl-5-Nitropyridin-2-Amine requires a deep understanding of technical specifications beyond simple CAS matching. By prioritizing vendors who provide detailed COAs, validated HPLC methods, and transparent impurity profiles, pharmaceutical manufacturers can safeguard their production schedules. Focus on partners who demonstrate control over the nitration synthesis route and offer competitive commercial terms for industrial volumes. This diligence ensures that the intermediate quality supports the efficacy and safety of the final therapeutic product.